These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12815593)

  • 1. A phylogenetic approach to assessing the significance of missense mutations in disease genes.
    Santibáñez Koref MF; Gangeswaran R; Santibáñez Koref IP; Shanahan N; Hancock JM
    Hum Mutat; 2003 Jul; 22(1):51-8. PubMed ID: 12815593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
    Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
    Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective pressures at a codon-level predict deleterious mutations in human disease genes.
    Arbiza L; Duchi S; Montaner D; Burguet J; Pantoja-Uceda D; Pineda-Lucena A; Dopazo J; Dopazo H
    J Mol Biol; 2006 May; 358(5):1390-404. PubMed ID: 16584746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.
    Mathe E; Olivier M; Kato S; Ishioka C; Hainaut P; Tavtigian SV
    Nucleic Acids Res; 2006; 34(5):1317-25. PubMed ID: 16522644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IARC TP53 database: new online mutation analysis and recommendations to users.
    Olivier M; Eeles R; Hollstein M; Khan MA; Harris CC; Hainaut P
    Hum Mutat; 2002 Jun; 19(6):607-14. PubMed ID: 12007217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The UMD TP53 database and website: update and revisions.
    Hamroun D; Kato S; Ishioka C; Claustres M; Béroud C; Soussi T
    Hum Mutat; 2006 Jan; 27(1):14-20. PubMed ID: 16278824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A highly sensitive detection method for somatic mutations in p53 gene.
    Sato T; Sato A; Ishihara H; Konishi K
    Rinsho Byori; 2003 Feb; 51(2):98-106. PubMed ID: 12690626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features.
    Walker DR; Bond JP; Tarone RE; Harris CC; Makalowski W; Boguski MS; Greenblatt MS
    Oncogene; 1999 Jan; 18(1):211-8. PubMed ID: 9926936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural assessment of single amino acid mutations: application to TP53 function.
    Yip YL; Zoete V; Scheib H; Michielin O
    Hum Mutat; 2006 Sep; 27(9):926-37. PubMed ID: 16917930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
    Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time for a unified system of mutation description and reporting: a review of locus-specific mutation databases.
    Claustres M; Horaitis O; Vanevski M; Cotton RG
    Genome Res; 2002 May; 12(5):680-8. PubMed ID: 11997335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatic analysis of protein structure-function relationships: case study of leukocyte elastase (ELA2) missense mutations.
    Thusberg J; Vihinen M
    Hum Mutat; 2006 Dec; 27(12):1230-43. PubMed ID: 16986121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the relative importance of the biophysical properties of amino acid substitutions associated with human genetic disease.
    Terp BN; Cooper DN; Christensen IT; Jørgensen FS; Bross P; Gregersen N; Krawczak M
    Hum Mutat; 2002 Aug; 20(2):98-109. PubMed ID: 12124990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian approach to discovering pathogenic SNPs in conserved protein domains.
    Cai Z; Tsung EF; Marinescu VD; Ramoni MF; Riva A; Kohane IS
    Hum Mutat; 2004 Aug; 24(2):178-84. PubMed ID: 15241800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
    Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
    Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs).
    Gorlov IP; Gorlova OY; Frazier ML; Amos CI
    Mutat Res; 2004 Oct; 554(1-2):175-83. PubMed ID: 15450416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phylogenetic evidence for deleterious mutation load in RNA viruses and its contribution to viral evolution.
    Pybus OG; Rambaut A; Belshaw R; Freckleton RP; Drummond AJ; Holmes EC
    Mol Biol Evol; 2007 Mar; 24(3):845-52. PubMed ID: 17218639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53.
    Gorlov IP; Gorlova OY; Amos CI
    Hum Mutat; 2005 Nov; 26(5):446-54. PubMed ID: 16173033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genetic variations of the tumor suppressor TP53: outstanding and strategies of analysis].
    Rangel-López A; Piña-Sánchez P; Salcedo M
    Rev Invest Clin; 2006; 58(3):254-64. PubMed ID: 16958302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.